Cripto as a target for cancer immunotherapy

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.9, Iss.2, 2005-04, pp. : 383-394

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

WT1 as a Novel Target Antigen for Cancer Immunotherapy

Current Cancer Drug Targets, Vol. 2, Iss. 1, 2002-03 ,pp. : 45-54

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the embryonic gene Cripto-1 in cancer and beyond

By Bianco Caterina Salomon David S

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 12, 2010-12 ,pp. : 1739-1749

Informa Healthcare

Access to resources Recommend Favorite

Fas ligand: a potential target for therapeutic induction of apoptosis and enhancing immunotherapy in cancer

By O'Connell J.

Expert Opinion on Therapeutic Targets, Vol. 3, Iss. 4, 1999-12 ,pp. : 601-611

Informa Healthcare

Access to resources Recommend Favorite

Immunotherapy for Prostate Cancer

Current Pharmaceutical Design, Vol. 12, Iss. 7, 2006-03 ,pp. : 807-817

Bentham Science Publishers

Access to resources Recommend Favorite

Cancer Immunotherapy Companies

Pharmaceutical Innovation, Vol. 11, Iss. 3, 2002-04 ,pp. : 45-48

Adis International

Access to resources Recommend Favorite